Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 02, 2022 at 08:00 AM EST

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on February 1, 2022, the Company granted an equity-based award pursuant to the Company’s 2019 Inducement Stock Incentive Plan to one newly-hired, non-executive employee. This inducement grant was approved by the Company’s compensation and talent strategy committee pursuant to a delegation by the Company’s board of directors and were made as a material inducement to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation.

The inducement grant consisted of non-statutory stock option to purchase 14,000 shares of the Company’s common stock.

The stock options each have an exercise price of $14.43 per share, equal to the closing price of Iveric Bio’s common stock on February 1, 2022. The stock option has a ten-year term and vests over four years, with 25% of the shares underlying the option vesting on February 1, 2023 and an additional 2.0833% of the shares underlying the option vesting at the end of each successive month thereafter. The vesting of the grant is subject to the employee’s continued service with the Company through the applicable vesting date. The inducement grant is subject to the terms and conditions of award agreement covering the grant and the Company’s 2019 Inducement Stock Incentive Plan.

Iveric Bio

Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retina diseases including all stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.

ISEE-G